SJG 136
Blastic Phase Chronic Myelogenous Leukemia
National Cancer Institute (NCI)Small moleculePhase 1Dormant
C
37/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 22/ 100
- Competitive Position
- 89/ 100
Competitive context
43 Active assets in the Blastic Phase Chronic Myelogenous Leukemia cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Fludarabine Ohio State University Comprehensive Cancer Center | Phase 2 | BBB |
Cyclophosphamide Ohio State University Comprehensive Cancer Center | Phase 2 | BBB |
TACROLIMUS University of Michigan Rogel Cancer Center | Phase 2 | BB |
Imatinib The University of Hong Kong | Phase 2 | BB |
Nilotinib The University of Hong Kong | Phase 2 | BB |
View all 50 →
Same molecule, other indications
SJG 136 is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →